BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22376081)

  • 1. Higher morning to evening ratio in total dose of twice-daily biphasic insulin analog might be effective in achieving glucose control in patients with poorly controlled type 2 diabetes.
    Lee YH; Lee BW; Kwon HJ; Kang ES; Cha BS; Lee HC
    Diabetes Technol Ther; 2012 Jun; 14(6):508-14. PubMed ID: 22376081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
    Garber AJ; Wahlen J; Wahl T; Bressler P; Braceras R; Allen E; Jain R
    Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The optimal morning:evening ratio in total dose of twice-daily biphasic insulin analogue in poorly controlled Type 2 diabetes: a 24-week multi-centre prospective, randomized controlled, open-labelled clinical study.
    Jung CH; Park JY; Cho JH; Yoon KH; Yang HK; Lee YH; Cha BS; Lee BW
    Diabet Med; 2014 Jan; 31(1):68-75. PubMed ID: 24118113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humalog Mix50 before carbohydrate-rich meals in type 2 diabetes mellitus.
    Roach P; Arora V; Campaigne BN; Mattoo V; Rangwala S;
    Diabetes Obes Metab; 2003 Sep; 5(5):311-6. PubMed ID: 12940868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of premeal injection time in insulin therapy: Humalog Mix25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits.
    Coscelli C; Iacobellis G; Calderini C; Carleo R; Gobbo M; Di Mario U; Leonetti F; Galluzzo A; Pirrone V; Lunetta M; Casale P; Paleari F; Falcelli C; Valle D; Camporeale A; Merante D
    Acta Diabetol; 2003 Dec; 40(4):187-92. PubMed ID: 14740279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide.
    Roach ; Koledova E; Metcalfe S; Hultman C; Milicevic Z;
    Clin Ther; 2001 Oct; 23(10):1732-44. PubMed ID: 11726007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus.
    Niskanen L; Jensen LE; Råstam J; Nygaard-Pedersen L; Erichsen K; Vora JP
    Clin Ther; 2004 Apr; 26(4):531-40. PubMed ID: 15189750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous glucose monitoring with Humalog Mix 25 versus Humalog Mix 50, twice daily: a comparative pilot study -results from the Jikei-EValuation of insulin Lispro mixture on pharmacodynamics and glycemic VariancE (J-EVOLVE) study.
    Nishimura R; Tsujino D; Taki K; Morimoto A; Tajima N
    Cardiovasc Diabetol; 2010 May; 9():16. PubMed ID: 20438630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of twice-daily injections of premixed insulin analog on glycemic control in type 2 diabetic patients.
    Shimizu H; Monden T; Matsumura M; Domeki N; Kasai K
    Yonsei Med J; 2010 Nov; 51(6):845-9. PubMed ID: 20879049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of prandial premixed therapy using insulin lispro mix 50/50 3 times daily compared with progressive titration of insulin lispro mix 75/25 or biphasic insulin aspart 70/30 twice daily in patients with type 2 diabetes mellitus: a randomized, 16-week, open-label study.
    Farcasiu E; Ivanyi T; Mozejko-Pastewka B; Birkus Z; Csog J; Kowalska I; Coetzer TF; Bulgurlu S; Schinzel B; Kiljanski J
    Clin Ther; 2011 Nov; 33(11):1682-93. PubMed ID: 22036246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humalog Mix25 improves 24-hour plasma glucose profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus.
    Herz M; Arora V; Campaigne BN; Scholtz HE; Potgieter MA; Mollentze W
    S Afr Med J; 2003 Mar; 93(3):219-23. PubMed ID: 12768948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of the timing of Humalog Mix25 injections on blood glucose fluctuations in the postprandial period in elderly patients with type 2 diabetes.
    Galic E; Vrtovec M; Bozikov V; Schwarzenhofer M; Milicevic Z
    Med Sci Monit; 2005 Dec; 11(12):PI87-92. PubMed ID: 16319804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group.
    Roach P; Trautmann M; Arora V; Sun B; Anderson JH
    Clin Ther; 1999 Mar; 21(3):523-34. PubMed ID: 10321421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin lispro 25/75 and insulin lispro 50/50 as starter insulin in Japanese patients with type 2 diabetes: subanalysis of the CLASSIFY randomized trial.
    Watada H; Imori M; Li P; Iwamoto N
    Endocr J; 2017 Jul; 64(7):705-717. PubMed ID: 28539526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group.
    Roach P; Yue L; Arora V
    Diabetes Care; 1999 Aug; 22(8):1258-61. PubMed ID: 10480767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
    Blonde L; Merilainen M; Karwe V; Raskin P;
    Diabetes Obes Metab; 2009 Jun; 11(6):623-31. PubMed ID: 19515182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).
    Raskin P; Matfin G; Schwartz SL; Chaykin L; Chu PL; Braceras R; Wynne A
    Diabetes Obes Metab; 2009 Jan; 11(1):27-32. PubMed ID: 17941873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.